Related Experiment Videos
Antibody-Based targeting of angiogenesis
1Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zürich.
Critical Reviews in Therapeutic Drug Carrier Systems
|July 10, 2001
Summary
Monoclonal antibodies targeting new blood vessel growth (angiogenesis) show promise for treating diseases like cancer. These antibodies act as molecular vehicles, offering new diagnostic and therapeutic possibilities.
Area of Science:
- Biomedical research
- Immunology
- Oncology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial in diseases like cancer, ocular disorders, rheumatoid arthritis, and psoriasis.
- Targeting aberrant angiogenesis is a key strategy in disease treatment.
Purpose of the Study:
- To review advancements in generating monoclonal antibodies that specifically target newly formed blood vessels.
- To explore the potential of these antibodies as diagnostic and therapeutic agents.
Main Methods:
- Review of recent scientific literature on monoclonal antibody development.
- Focus on antibodies recognizing and targeting in vivo angiogenesis.
- Emphasis on antibodies that differentiate between new and mature blood vessels.
Main Results:
- Progress has been made in creating monoclonal antibodies with high specificity for angiogenic vessels.
- These antibodies can target new vasculature while sparing healthy tissues and mature vessels.
- Demonstrated potential for selective targeting in disease contexts.
Conclusions:
- Monoclonal antibodies offer a promising approach for selective targeting of angiogenesis.
- These antibodies can serve as effective molecular vehicles for diagnostics and therapeutics.
- Significant potential for advancing treatment strategies in angiogenesis-driven diseases.